Authors: Wong ICK, et al.
Title: Factors influencing the incidence of lamotrigine-related skin rash.
Reference: Ann Pharmacother 1999;33:1037-42.
Purpose: To determine the incidence of and risk factors for lamotrigine-related rash.
Study design: Retrospective, case record survey at five epilepsy referral centers in the UK (December 1993 to September 1996).
Follow up: Not applicable.
Patients: 1,050 epilepsy patients.
Treatment: Lamotrigine 6.25–100 mg/day (mean range of the starting dose).
Results: A significant reduction in the incidence of serious rash, from 1.5% to 0%, occurred after the starting dose was reduced in 1994 following recommendation by the manufacturer. Concurrent sodium valproate and a high starting daily dosage increased the risk of rash.